The inhibition of CF‐enriched lncRNA Meg3 prevented the cardiac MMP‐2 induction, resulting in decreased cardiac fibrosis and enhanced diastolic performance.20 These studies suggested that lncRNA might supply novel approaches to cardiac fibrosis treatment; however, all these lncRNAs are studied in CFs. This evidence concerns the gene MMP2 and myalgic encephalomeyelitis/chronic fatigue syndrome.